EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   3.2.1.207 | Carcinogenesis |
31320625 |
PRKCSH contributes to tumorigenesis by selective boosting of IRE1 signaling pathway. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
3
1
0 |
| 3.2.1.207 | Carcinogenesis |
31420557 |
Publisher Correction: PRKCSH contributes to tumorigenesis by selective boosting of IRE1 signaling pathway. |
therapeutic application
unassigned |
1
0 |
| 3.2.1.207 | Carcinoma |
21371016 |
PRKCSH GAG trinucleotide repeat is a mutational target in gastric carcinomas with high-level microsatellite instability. |
therapeutic application
unassigned |
1
0 |
| 3.2.1.207 | Carcinoma |
28929344 |
Glucosidase II beta subunit (GluII?) plays a role in autophagy and apoptosis regulation in lung carcinoma cells in a p53-dependent manner. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
3
1 |
| 3.2.1.207 | Cysts |
12529853 |
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. |
unassigned |
0 |
| 3.2.1.207 | Cysts |
15057895 |
Abnormal hepatocystin caused by truncating PRKCSH mutations leads to autosomal dominant polycystic liver disease. |
causal interaction
unassigned |
4
0 |
| 3.2.1.207 | Cysts |
16835903 |
Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease. |
causal interaction
diagnostic usage
ongoing research
unassigned |
4
1
2
0 |
| 3.2.1.207 | Cysts |
18224332 |
Cysts of PRKCSH mutated polycystic liver disease patients lack hepatocystin but express Sec63p. |
causal interaction
unassigned |
2
0 |
| 3.2.1.207 | Cysts |
18419150 |
Hepatocystin is not secreted in cyst fluid of hepatocystin mutant polycystic liver patients. |
unassigned |
0 |
| 3.2.1.207 | Cysts |
19308730 |
PRKCSH Genetic Mutation Was Not Found in Taiwanese Patients with Polycystic Liver Disease. |
causal interaction
ongoing research
unassigned |
1
4
0 |
